Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN - 2Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
- 3Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- 4'Fertiliser costs mean I'm better off not planting'
- 5Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- How to get tickets for AC/DC's 2026 'Power Up' Tour
- The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- Vote in favor of Your #1 4\u00d74 SUVs
- Rubble, mud and hair: How to rebuild a home in Gaza
- Trump signs a law returning whole milk to school lunches
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
